AccessHealth MA
Formerly known as Community Research Initiative (CRI)

1/19/2018

ATLAS-2M Web Summary

Trial Nickname: ATLAS-2M

Full Name: Efficacy, Safety and Tolerability Study of Long-acting Cabotegravir Plus Long-acting Rilpivirine (CAB LA + RPV LA) in Human-immunodeficiency Virus-1 (HIV-1) Infected Adults

Participant Overview: This study will divide subjects into two groups. Group 1 will include subjects receiving current ART standard of care therapy, Group 2 will include subjects currently receiving long-acting cabotegravir (CAB LA) and long-acting rilpivirine (RPV LA) in the current ATLAS study. Both groups will be randomized to receive CAB LA + RPV LA in either four-week or eight-week intervals.

Major Eligibility Criteria:

- At least 18 years old
- Currently suppressed viral load for longer than 6 months on the first treatment regimen

Description:

This study will evaluate the safety and effectiveness of switching to long-acting cabotegravir (CAB LA) and long-acting rilpivirine (RPV LA) administered every eight weeks compared to CAB LA + RPV LA administered every four weeks (Q4W) over a 48-week treatment period in approximately 1,020 adult HIV-1 infected subjects.

Participants will receive injections of the medication every four or eight weeks onsite at CRI's research facility in Boston.

Study Sponsor: ViiV Healthcare

For more information, please contact: Our Research Team, 617.502.1707 or info@accesshealthma.org

***Please note this Clinical Trial and Summary was started while AccessHealth MA was still known as Community Research Initiative (CRI). This information is still relevant.**